BIND Therapeutics (BIND) Reports In-Line Q2 Loss

BIND Therapeutics (NASDAQ: BIND) reported Q2 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $3.88 million.

For earnings history and earnings-related data on BIND Therapeutics (BIND) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• SanDisk unveils long-term growth strategy at 2026 Investor Day; Shares surge 12%
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c